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Background: Peritoneal mesothelioma is a very rare diagnosis with an incidence of 1 case per
4e5 million of the population. It accounts for 20e30% of all mesothelioma type cancers. There
is great interest in this disease entity amongst the medical community and indeed the general
population due to the well-substantiated link between asbestos related exposure and meso-
thelioma.
Case presentation: In this article we report a case of a 77 year old man who presented with
a oneweek history of breathlessness and a right pleural effusion. An incidental right upper quad-
rant abdominal mass was noted leading to ultrasound and subsequent CT scans. A large subhe-
patic mass was identified, in addition to pleural calcification and thickening. Biopsy and
histological examination of the abdominal mass suggested a spindle cell tumour, most likely
a mesothelioma. Thoracocentesis and cytology of the pleural fluid confirmed the diagnosis of
a malignant mesothelioma. Our patient is a retired dairy farmer. A detailed occupational history
revealed likely asbestos exposure when he worked as a plumber, approximately 50 years ago.
Discussion: Patients with peritoneal mesothelioma often present late, and as a result treatment
is often palliative. Interventions include cytoreductive (debulking) surgery and intraperitoneal
chemotherapy or radiotherapy. Peritoneal mesothelioma is a very rare disease entity, yet a diag-
nosis to be considered in a patient with an abdominal mass, previous asbestos exposure, and
pleural calcification.
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Mesothelioma is a malignancy of the mesothelium, the
serosal membrane that covers and protects the internal
organs of the body. Malignant mesotheliomas predomi-
nantly affect the pleural mesothelium (50e60%) but can
affect any anatomical mesothelial surface including the
peritoneum (20e30%), the pericardium or indeed the tunica
Figure 2 Histology of abdominal mass showing spindle cells.
Peritoneal mesothelioma 81vaginalis testis of the male, or tunica serosa uteri in the
female patient. The incidence of peritoneal mesothelioma
worldwide is approximately one case per 4e5 million of the
population, with an incidence of all mesotheliomas being in
the range of one per 1 million. However, the incidence
rates in industrialized countries are greater and ranges
between 0.5 and three cases per million in men and
between 0.2 and two cases per million in women.1 With
malignant peritoneal mesothelioma being a relatively rare
diagnosis there is limited data on the natural history of this
condition.
Case report
A 77 year old man with a background history of Alzheimer’s
disease, ischaemic heart disease, carotid artery stenosis
and gastric ulcers, presented with a one week history of
breathlessness. There was no associated cough, haemopt-
ysis, weight loss, anorexia or symptoms suggestive of heart
failure. Initial assessment revealed reduced air entry and
crepitations at the right base. He was apyrexial and
inflammatory markers were slightly elevated (WCC 11.4
and CRP 36). A chest X-ray suggested right basal consoli-
dation with an associated small effusion. He was initially
treated for a community acquired pneumonia.
Further to vague abdominal discomfort and a palpable
fullness in the right upper quadrant, an USS was performed.
This showed a large (13 cm) subhepatic heterogenous soft
tissue mass. A CT of chest, abdomen and pelvis (Fig. 1)
confirmed the presence of this mass. In addition, the mass
was felt to be infiltrating the anterior abdominal wall and
was closely related to the hepatic flexure. There were
upper lobe emphysematous changes in the chest with
bilateral pleural thickening and calcifications, in addition
to an increasing right pleural effusion. A previous abdom-
inal ultrasound 4 years ago was normal. Despite the close
relation of the mass to the ascending colon, our patient did
not have any signs of bowel obstruction.
An ultrasound-guided biopsy of the abdominal mass was
performed, and histology identified a spindle cell tumourFigure 1 CT scan of abdomen.(Fig. 2). Possibilities at this stage were malignant meso-
thelioma, fibromatosis or gastrointestinal stromal tumour.
Subsequent thoracocentesis and examination of pleural
fluid confirmed the diagnosis of a malignant mesothelioma.
Our patient was a retired dairy farmer. Revisiting his
occupational history revealed that he had worked as an
assistant plumber for at least 2 years, approximately 50
years ago. He acknowledged working closing with pipes,
and possible exposure to asbestos. After review by a respi-
ratory specialist, he received talc pleurodesis. Due to the
advanced nature of his condition he is not for any aggres-
sive treatment. Management is very much palliative.
Discussion
Malignant peritoneal mesothelioma is a neoplasm origi-
nating from the mesothelial surface lining cells of the
peritoneal serous cavities. Approximately 20e30% of all
mesotheliomas affect the peritoneum. The association
between asbestos exposure and peritoneal mesothelioma is
less strong than in the case of pleural mesothelioma.1 In
approximately 50% of peritoneal mesothelioma cases there
is a history of asbestos exposure. It appears that the risk of
mesothelioma and the risk of subsequent mortality corre-
lates with cumulative exposure to asbestos fibres and also
the type of fibre. Patients who have been exposed only or
predominantly to chrysotile asbestos fibres contribute to
a lower proportion of total deaths from peritoneal meso-
thelioma than those individuals exposed to amphibole
fibres or mixed type of asbestos fibres.1 The latent period
for asbestos-related peritoneal mesothelioma is shorter
than that for the more common pleural mesothelioma, 20e
30 years vs 30e40 years.2
Whilst asbestos is identified as the main known cause of
the disease, other risk factors are likely to be involved in its
aetiology and pathogenesis. Case reports have also noted
peritoneal mesothelioma in patients following exposure to
erionite and the radiological dye Thorotrast.3,4 The role of
other suspected risk factors, such as simian virus 40 infec-
tion and genetic predisposition, is unclear at present.
Peritoneal mesothelioma has a male predominance, and
a median age of 65e69 years old.2 Although Deraco et al.
82 C. Pollock et al.report a patient diagnosed with a peritoneal mesothelioma
aged just 22 years old.5 There is also evidence of
a geographical variance in the incidence of peritoneal
mesotheliomas amongst different populations, the highest
incidence found in the Netherlands and Scotland.1
The diagnosis of peritoneal mesothelioma is often
delayed, due to the relatively insidious mild non-specific
symptomatology of the disease.6 The common presenting
symptoms are vague and non-specific and include weight
loss, usually with a full abdomen, malaise, and abdominal
discomfort.
As with all mesotheliomas, the diagnosis of peritoneal
mesothelioma can be challenging. Two peritoneal meso-
thelioma subtypes have been described based on findings
on CT scanning. The ‘dry’ type of mesothelioma is associ-
ated with multiple small masses or a single dominant
localized mass on CT with little or no ascites. In the ‘‘wet’’
type of mesothelioma, CT reveals widespread small nodules
with ascites present, but no dominant mass.2
If ascites is present, paracentesis may be performed to
obtain a sample of peritoneal fluid for cytological exami-
nation. However, fluid analysis offers limited diagnostic
value. Instead a tissue biopsy of the intra-abdominal mass is
required and subsequent immunocytochemical staining will
yield a definitive diagnosis.
There are limited therapeutic options available for the
physician when treating a patient with a malignant meso-
thelioma arising from the peritoneal cavity.7 As the diag-
nosis often made late in the disease process, the majority
of patients are managed with palliative care. Palliative
treatment is designed to reduce the rate at which the
cancer spreads, and to provide symptomatic relief.
Options for those patients who are deemed suitable for
more aggressive management are also limited. Surgery
alone and/or intraperitoneal chemotherapy alone have
proven to be similarly ineffective. In recent years, multi-
modality treatment of peritoneal mesothelioma has largely
become the treatment of choice. The management of these
patients includes cytoreductive (debulking) surgery
involving the removal of all or nearly all visible tumour,
combined with either intraperitoneal chemotherapy or
radiotherapy.7 This multimodality treatment approach with
cytoreductive surgery and intraperitoneal chemotherapy
has resulted in a median survival of 50e60 months.8,9
Overall survival remains poor; in the USA Surveillance,
Epidemiology and End Results (SEER) cancer registry data
median survival is 10 months and relative 5-year survival is
16%.10 In selected clinical series a longer survival has been
reported with median survival greater than 50 months.11
Female patients have a significantly better prognosis than
male patients.12
Feldman et al. report that favourable outcome is asso-
ciated with age, tumour patho-biology, lack of invasive
tumour growth, and minimal residual disease after tumour
resection.7 In addition to the completeness of cytor-
eduction, the performance status and mitotic count are the
strongest factors influencing overall survival and the best
determinants of outcome.5
Altima (pemetrexed) approved by the U.S. Food and
Drug Administration authority in 2003, is the first medicine
developed to specifically treat mesothelioma. Altima used
in combination with cisplatin, a commonly usedchemotherapy agent, has been shown in clinical trials to be
associated with an increased survival for mesothelioma
patients.13 It is an anti-folate antineoplastic agent that acts
by disrupting folate dependent metabolic processes.
Although no biological markers (epidermal growth factor
receptor, p16, matrix metalloproteinase 2 and matrix
metalloproteinase 9) have been shown to be of prognostic
value,5 recent research in 2007 has identified a tumour
marker that may be useful in monitoring tumour response
to therapy and for screening at risk individuals. Robinson
et al. identified a soluble mesothelin-related protein
(SMRP) present in the serum that early clinical trials have
identified as a marker of malignant mesothelioma with
a sensitivity rate of 83% and specificity rate of 95%. Changes
in serum SMRP levels are thought to parallel the clinical
course and mesothelioma tumour size.14Conclusion
Peritoneal mesothelioma is a very rare disease entity. This
case report discusses the diagnostic challenges, treatment
and recent advances in the area of malignant peritoneal
mesothelioma. In a patient presenting with an unusual
abdominal mass and co-existing pleural calcification, it may
be important to explore a history of previous asbestos
exposure. Recent research into peritoneal mesothelioma
has identified a tumour marker that may be useful, not only
in monitoring tumour response to therapy, but also for
screening at risk individuals, i.e. those patients who have
previous occupational asbestos exposure.
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